Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Aprepitant Capsules USP, 40 mg, 80 mg, and 125 mg, the generic version of Emend Capsules, 40 mg, 80 mg, and 125 mg, of Merck Sharp & Dohme Corporation.
According to IMS Health sales data for the 12 month period ending August 2017, the Emend Capsules, 40 mg, 80 mg, and 125 mg market achieved annual sales of approximately $64.9 million.
Glenmark’s current portfolio consists of 127 products authorized for distribution in the US marketplace and 60 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
